Semler Scientific reported Q4 2023 revenues of $15.1 million, a 9% increase year-over-year, and net income of $4.2 million, a 31% increase year-over-year. The company's cash balance increased to $57.3 million. They are seeking FDA clearance with expanded labeling for use as an aid in the diagnosis of other cardiovascular diseases.
Fourth quarter revenues increased by 9% to $15.1 million.
Fourth quarter net income increased by 31% to $4.2 million.
Full year revenues increased by 20% to $68.2 million.
Cash balance increased to $57.3 million.
Semler Scientific remains focused on marketing its product and seeking a new 510(k) clearance from the FDA with expanded labeling for use as an aid in the diagnosis of other cardiovascular diseases.